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Abstract
Background: Non-infectious inflammatory diseases of the canine central nervous system (CNS) are common
idiopathic disorders grouped under the term meningoencephalomyelitis of unknown origin (MUO). Ante mortem
diagnosis is achieved via assessment of clinical signs, magnetic resonance imaging (MRI), and cerebrospinal fluid
(CSF) analysis, but the definitive diagnosis needs histopathological examination. MUO are mostly considered as
autoimmune CNS disorders, so that suppressing the immune reaction is the best management method for patients.
Mesenchymal stem cells (MSCs) are under investigation to treat autoimmune and degenerative disorders due to
their immunomodulatory and regenerative properties. This study aims to verify the safety, feasibility, and efficacy of
MSCs treatment in canine idiopathic autoimmune inflammatory disorders of the CNS.
Methods: Eight dogs presented with acute onset and rapid progression of multifocal neurological signs were
selected to the study. In all patients’ physical and neurological examinations, MRI and CSF analyses were performed.
Clinical diagnosis in all cases was MUO. All selected dogs responded initially to immunosuppressive drugs (prednisone
and a combination of prednisolone and cytosine arabinoside) but developed undesirable side effects. For all eight
dogs, the owners considered euthanasia but accepted cell therapy as a last possibility. Autologous bone marrow MSCs
(BMMSCs), isolated, cultured, and expanded, were administered by intrathecal (IT) injection in the cisterna magna
intravenously (IV) and by intra-arterial (IA) injection in the right carotid artery. Adverse effects and clinical response were
monitored for 6 months up to 2-year follow-up.
Results: The use of autologous BMMSCs in dogs with MUO was safe for IT, IV, and IA injections. No major short- or
long-term adverse effects were registered. All the dogs presented early improvement in their general and neurological
conditions, with particular effect on cervical pain. The group of dogs treated by IT+IA administration showed a shorter
time of reaction to therapy compared to the group treated by IT+IV administration.
Conclusions: MSCs treatment in dogs affected by MOU is safe and feasible. A larger group of dogs is needed to
confirm these results as well as CNS histology in order to better understand the underlying mechanisms.
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Background
The canine non-infectious inflammatory diseases of the
central nervous system (CNS) are common diseases that
can affect the brain, spinal cord, and/or the meninges.
Clinical signs of non-infectious CNS inflammatory disor-
ders are frequently very similar to those of infectious
CNS diseases and even those of neoplasia [1]. The major
diagnostic decision is between infectious and non-
infectious diseases. Recently, the term meningoencephal-
itis of unknown origin (MUO) has been introduced to
all clinically diagnosed cases based on advanced imaging
and cerebrospinal fluid (CSF) analysis of non-infectious
inflammatory CNS disease [1–3]. MUO includes all the
specific subtypes of non-infectious inflammatory disease
that can be identified through histopathology, including
granulomatous meningoencephalomyelitis (GME) and
necrotizing encephalitis (NE), but does not include the
diseases without evidence of explicit CNS involvement,
such as steroid-responsive meningitis-arteritis (SRMA)
[1]. The inclusive term NE incorporates necrotizing
meningoencephalitis (NME) and necrotizing leukoence-
phalitis (NLE) because of the overlapping in clinical
signs, signalment, and neuropathology. They differenti-
ate on the region of the brain involved [1, 2]. Particu-
larly, NME is an idiopathic inflammatory disease of the
CNS that is characterized by prominent necrosis and in-
filtration of inflammatory cells, including lymphocytes,
plasma cells, and monocytes or histiocytes into the cere-
bral cortex and/or white matter, hippocampus, thalamus,
and leptomeninges. NME has been reported in various
canine breeds, including the Pug [4, 5], Maltese [6, 7],
Shih tzu [8], Papillon [8], Chihuahua [9], Pekingese [10],
Yorkshire terrier [11, 12], and French bulldog [13]. The
areas of necrosis and inflammatory cell infiltration are
localized in the cerebral cortex and subcortical region in
most NME cases, whereas in a few breeds, such as the
Yorkshire terrier and French bulldog, the lesions are
predominately observed in the white matter, and the dis-
ease is called NLE.
GME represents up to 25 % of all canine inflammatory
CNS diseases. Neurological signs are non-specific and
can be localized to the forebrain, brainstem, or spinal
cord or appear as a multifocal syndrome [1, 14]. The
clinical presentation correlates with three pathological
distributions: multifocal or disseminated (clinically char-
acterized by acute onset and rapid progression of neuro-
logical signs, fever, paraspinal hyperesthesia, mainly
localized to the cervical region); focal (slower progres-
sion of neurological signs, the differential diagnosis in-
cluding intracranial neoplasia); or ocular (optic neuritis,
anterior, and posterior uveitis). GME’s neuropathological
lesions consist of perivascular cuffs composed of lym-
phocytes, plasma cells, macrophages, and some neu-
trophils, as well as granulomatous lesions containing
epithelioid cells, mainly in the cerebellum and brain-
stem [15].
The etiopathogeneses of GME and NE remain un-
clear. MUO has long been assumed to have an auto-
immune and genetic pathogenesis. Autoimmune diseases
arise from dysregulation of either or both of the innate
and adaptive immune systems to produce inflammatory
responses leading to cellular dysfunction and tissue
destruction. In general, major factors that contribute
to the development of autoimmunity are genetic sus-
ceptibility and environmental factors (e.g., infections,
tissue injury). Nevertheless, a trigger factor is as-
sumed to initiate signs of disease in each specific dog
at a specific time [15, 16]. Suspected agents include
environmental or infectious antigenic triggers that
might activate autoreactive cells in the CNS, although
no such agent has yet been incriminated in the devel-
opment of MUO [17, 18]. Susceptibility genes may
confer susceptibility or protection for autoimmunity
by influencing the maintenance of self-tolerance. One
of the most important features of the CNS is its rela-
tive isolation from the peripheral immune system,
which has important implications regarding the
pathogenesis, diagnostic criteria, and therapy for in-
flammatory CNS diseases [19]. The blood-brain bar-
rier (BBB) and the blood-spinal cord barrier implies
that there is “gating” of the flow of cells and macro-
molecules from the systemic circulation to the CNS
[20] and that CNS is immunocompetent and actively
interacts with the peripheral immune system [21]. Al-
though neuroinflammation has been investigated in
several spontaneous canine CNS diseases, mechanisms
still remain enigmatic for the MUOs. Immunomodu-
lation through cross-talk between the periphery
(extraneural) and the CNS, and how to limit cytotox-
icity and enhance neuroprotection, would help iden-
tify appropriate targets for immune-based therapy.
Administration of immunosuppressive doses of glu-
cocorticosteroids is the traditional primary treatment in
MUO in dogs which may help reduce inflammatory
and immune reactions during initial stage of the disease
[22]. This results in remission of clinical signs for a
period of time, but many dogs require sustained ther-
apy to avoid relapse. Prognosis is poor and long-term
therapy causes many complications [22, 23]. Adverse
effects such as polyuria-polydipsia, polyphagia, weight
gain, hepatotoxicity, iatrogenic hyperadrenocorticism,
and lethargy are frequently seen during long-term ther-
apy. Thus, alternative treatments for MUO are required
due to these disadvantages [22, 23].
Reported second-line immunosuppressive drug therap-
ies used for the treatment of MUO cases are procarba-
zine, cytosine arabinoside, lomustine, azathioprine, and
cyclosporine [1, 22, 23].
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Many of these drugs have potential risks for myelosup-
pression, hepatotoxicity, and gastrointestinal disturbance.
Convincing immunomodulatory features have been
ascribed to MSCs derived from the bone marrow, an
easily accessible and highly proliferative stem cell
source [24–27]. While the prominent benefit provided
by these multipotent adult stem cells has been largely
documented in several disease models, being charac-
terized by inflammatory reactions in the nervous sys-
tem (such as amyotrophic lateral sclerosis (ALS),
Parkinson’s disease, Alzheimer’s disease, or traumatic
injuries), it is noteworthy that the immunomodulatory
capacity of grafted MSCs does not necessarily depend
on cell-specific differentiation or the integration of
the grafted cells into the host tissue. It rather seems
that MSCs possess the potential to establish a transi-
ent neurotrophic microenvironment that is beneficial
and supports tissue healing, repair, and regeneration.
In fact, grafted MSCs have been recently described as
“in vivo drugstores,” synthesizing and secreting paracrine
factors, which mediate therapeutic benefits [28–31].
Supporting this concept, two in vitro studies have
documented that MSCs can release growth/neurotrophic
factors as well as anti-inflammatory proteins and modu-
late microglial responses to pro-inflammatory stimuli
[32, 33]. Moreover, single intra-brain or intravenous
injections were shown to ameliorate neuroinflamma-
tion and associated behavior in animal models of
neuropathic pain [34, 35].
In the present investigation, we evaluate the safety,
the feasibility, and the efficacy of MSC treatment in
canine idiopathic autoimmune inflammatory disorders
of the CNS.
Materials and methods
Dog population
MUO is a clinical diagnosis based on neurologic exam-
ination, cross-sectional imaging findings, and CSF ab-
normalities, supplemented by exclusion of infectious
diseases; definitive diagnosis requires histopathology. In
our study, we followed the guidelines proposed by
Granger and colleagues [14] in order to establish an ante
mortem presumptive diagnosis of MUO in the absence
of histopathologic diagnosis.
The study population consisted of eight dogs, four
males and four females, between 1 and 4 years old, re-
ferred to the San Michele Veterinary Hospital, Tavazzano
con Villavesco, Lodi, Italy, between 2009 and 2014. All
dogs were suspected of non-infectious inflammatory dis-
ease of CNS. The clinical diagnosis was supported by
signalment, history, neurologic examinations, complete
blood count, serum biochemistry profile, and cisterna
magna CSF collection.
CSF analysis consisted in Burker chamber cell counting,
cytological evaluation of an air-fixed, May-Grünwald
Giemsa-stained sediment and protein concentration.
Polymerase chain reaction (PCR) analysis performed
for toxoplasmosis, neosporosis, canine distemper, ehr-
lichiosis, and leishmaniasis was negative. MRI has been
performed using a 0.25T magnet (Esaote Vet MR
Grande). Imaging protocol consisted of eight sequences:
transverse and sagittal T2W FSE, dorsal fluid attenuated
inversion recovery (FLAIR), dorsal Hyce 3D, T1W trans-
verse SE, and T1W dorsal Turbo 3D. In all dogs, the last
two sequences were repeated after the intravenous ad-
ministration of 0.3 ml/Kg BW contrast medium (Omnis-
can GE Healthcare).
In order to perform MRI and CSF collection dogs were
sedated with medetomidine (5 μg/kg) and buprenor-
phine (5 μg/kg) by intramuscular injection; after 20 min,
they were induced to general anesthesia with diazepam
(0.25 mg/kg) and propofol (4 mg/kg) then intubated
with an oro-tracheal catheter and maintained with iso-
flurane (MAC 1.1). In order to be included in the study,
each dog needed to present neurological signs, be posi-
tive to at least one out of the two parameters: MRI or
CSF and negative to PCR exams for the various infec-
tious diseases. Finally, in order to be eligible, all candi-
dates underwent thorax radiographs and abdominal
ultrasound, so that other diseases could be ruled out.
Treatment
Selection of a specific therapy protocol depended on the
clinician’s decision, the patient’s clinical status, and the
pet owner’s financial and personal considerations. Gen-
erally, all suspected MUO cases are treated in our hos-
pital initially by immunosuppressive doses of prednisone
(2 mg/kg/day) and tapered with response over the fol-
lowing months to achieve the lowest dose possible that
controls signs. When necessary, the therapy is supported
by cytosine arabinoside administered at 50 mg/m2 every
12 h as a subcutaneous bolus for two consecutive days
once every 3 to 4 weeks for 3 cycles and then increasing
progressively the interval between treatment cycles. If a
relapse occurred, the protocol is repeated with the initial
doses.
From all our MUO cases, eight dogs were selected for
two main reasons: first, they all relapsed after prednisone
was stopped and responded poorly to a second full dose
therapy, and second, the owners asked for euthanasia
but accepted cell therapy as a last possibility.
Three of the dogs were treated by a combination of
prednisone and cytosine arabinoside administered as de-
scribed above but developed undesirable side effects.
Three dogs presented seizures, one of them was treated
with phenobarbital (PB), 3 mg/kg twice a day, and the
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other two also with levatiracetam, 10 mg/kg every 8 h as
anticonvulsant therapy.
Ethics statement
All animal procedures involving MSCs were performed
in accordance with the guidelines defined by the Italian
Presidency of the Council of Ministers and following the
guidelines published by the General Directory of Animal
Health and Veterinary drugs of the Italian Ministry of
Health [36].
The owners of the eight dogs recruited for the MSC
treatment were thoroughly informed about the entire
procedure and signed a formal agreement with the San
Michele Veterinary Hospital in acceptance of the ther-
apy. Owners have also accepted that their dogs will
undergo post-mortem examination at the end of their
life.
BMMSCs collection, isolation, culture, and quality controls
Dogs were sedated and anesthetized, as previously de-
scribed, and with the animals in lateral recumbency, au-
tologous bone marrow (BM) was collected from the
proximal end of both humeri using a T-handle Jamshidi®
needle (14G for large dogs, 18G for small dogs).
Of BM, 40 ml was collected and diluted 1:4 with
heparinized culture medium (Dulbecco’s modified Eagle’s
medium (DMEM) with L-Glutamine, 4500 mg/L D-
Glucose, 25 mM HEPES, without sodium pyruvate and
supplemented with 10 % inactivated fetal bovine serum
and 1 % penicillin-streptomycin (Gibco, Life Technologies)
and 1 % Glutamax (Gibco, Life Technologies). BM
was diluted again 1:4 with Dulbecco’s phosphate buffered
saline (DPBS without calcium, magnesium—Gibco, Life
Technologies), and peripheral mononuclear cells (PBMCs)
were isolated using LeucoSepTM tubes preloaded with
Ficoll (Greiner Bio One). The PBMCs was harvested by a
pipette, inserted in an individual tube, and washed by cen-
trifugation in DPBS twice. The resultant cell precipitate
was suspended in culture medium supplemented with
EGF (Sigma) and bFGF (Gibco, Life Technologies). The
cell suspension was transferred to T25 flask (Greiner Bio
One) and incubated at 37.5 °C and 5 % humidified CO2.
The medium with non-adherent cells was discarded after
24 and 48 h, the cultures were carefully washed in DPBS
with calcium and magnesium (Gibco, Life Technologies),
and culture medium was replaced with a fresh portion.
The medium was then replaced every 2–3 days. After
attaining a sub confluent state, the cells were removed
with 0.05 % trypsin-EDTA (Gibco, Life Technologies) and
seeded again into new flasks at split ratio of 1:3. Cultures
were expanded for only three passages. MSCs were char-
acterized according to morphology, growth traits, and
cell-surface antigens profile (fluorescence-activated cell
sorting (FACS)). For FACS analysis 1 × 106 cells were
resuspended in each flow cytometry tubes containing
500 ml of DMEM with 10 % FBS and were labeled using
the following directly conjugated antibodies: CD45-
fluorescein isotyocianate (-fitc) (clone YKIX716.13, AbD
Serotec), CD14-pycoerythrin (-pe) (clone TUK4, AbD
Serotec), CD34-pe (clone 1H6, Pharmingen), CD117-pe
(clone ACK45, Pharmingen), and CD44-fitc (clone IM7,
Pharmingen). After 20-min incubation at 4 °C, tubes were
washed twice in PBS and acquired using a FacsCalibur
(Becton Dickinson) flow cytometer. Cells were identified
as a population of large and moderately complex cells
based on FSC vs SSC scattergram, and positivities were
expressed in percentage in comparison with appropriate
isotypic controls. Bacterial and fungi contaminations were
tested with microbiological analysis, and mycoplasma con-
tamination was excluded with DAPI stain. For DAPI,
500 ul of cell suspension at the third culture passage were
plated in a Petri culture dish and incubated for 48 h. The
cells were fixed with 4 % paraformaldehyde with 2 %
sucrose in DPBS, post-fixed with 70 % ethanol, and
put at −20 °C for at least 1 h. The cells were incu-
bated with DAPI (Sigma) 1:100000 for 15 min and
examined and photographed under a fluorescence
microscope.
BMMSCs administration
Bone marrow MSCs (BMMSCs) at passage three
(approximately 14 days of growth) were used for the
therapy. The dogs were sedated, induced to general
anesthesia, as previously described, and received their
autologous BMMSCs diluted in saline solution. Three
dogs received 2 × 106 cells intrathecally (IT) in cis-
terna magna and 4 × 106 cells by injection in the right
carotid artery after it has been surgically exposed as
routinely done for the intra-arterial (IA) administra-
tion of drugs [37].
Four dogs received 2 × 106 cells IT in the cisterna
magna and 0.5 × 106 cells/kg intravenously (IV). The last
dog, that was treated twice, had an IT+IV administra-
tions the first time and IT+IA the second time
(13 months after the first one) (Table 2).
Follow-up
Eventual adverse effects and clinical outcomes were
monitored up to 2 years and a minimum of 6 months, in
one case, after treatment with BMMSCs. Follow-up in-
cluded neurological examinations, urinalysis, complete
blood, and biochemistry work-up 3 months after treat-
ment. A control MRI and neurologic assessment were
done 6 months after treatment. If necessary, dogs who
had abnormal results, repeated the specific exams 1–
3 months later. During the whole 24 months, owners
and referring veterinarian forwarded their surveys on a
monthly base or whenever they considered it necessary.
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Histopathology
The brain and spinal cord and samples of major organs
were fixed in phosphate buffered 4 % formalin solution.
Tissue samples were routinely processed for histology,
and sections were stained with hematoxylin and eosin,
luxol fast blue, periodic acid-Schiff, Grocott’s methena-
mine silver, and Gram stainings.
Results
BMMSCs culture
The cultured MSCs consistently (>98 %) expressed their
classical surface markers and were negative for lympho-
cytes and hematopoietic cells (FACS analysis) and for
bacteria and fungal and mycoplasma contaminations.
Cultures were ready for administration within a max-
imum period of 14 days. In four cases, the cell quantity
obtained permitted cryoconservation of unused cells.
General and neurological status
At the time of presentation, neurologic examination re-
vealed non-specific signs, localized to forebrain, brain-
stem, cerebellum, or spinal cord, or appeared as a
multifocal syndrome. In most cases, clinical signs con-
sisted of an acute onset of cervical pain, tremors, ataxia,
paresis, and altered mental status and, in three cases,
seizures. A progressive deterioration of the clinical status
of all dogs was reported. The results of the collected
clinical data are presented in Table 1.
During the BMMSCs culture period, all dogs contin-
ued prednisolone therapy and seven dogs used tramadol
at 3 mg/kg/tid, due to paraspinal cervical pain. Owners
reported only mild effects of this therapy.
All dogs had normal blood work-up and urinalysis
through the follow-up period. No adverse effects
followed BMMSCs administration at any time, except
for one case in which a transitory hyperthermia was reg-
istered 24 h after BMMSCs delivery. Owners and refer-
ring veterinarians reported an initial improvement in
general and neurologic status within 5 days after treat-
ment in the IT+IA group of dog and 13 days after treat-
ment in the IT+IV group. In particular, paraspinal
hyperesthesia of the cervical region, which was a major
feature in all dogs, improved. This has been confirmed
in the first neurologic control 30 days after treatment,
together with improvement of behavior changes,
depression, proprioception and postural reactions,
ataxia, head tilt, and circling. After the first neuro-
logic control, improvements were variously progres-
sive through a maximum period of 6 months and
were not registered afterward. At 6 months, four dogs
were completely normal, one dog maintained mild
ataxia as a single clinical sign, two dogs needed to
continue anti-epileptic treatment but were otherwise
normal, and one dog died for reasons not related to
its neurologic disease.
After BMMSCs treatment, the two dogs under anti-
epileptic therapy presented reduction in seizures fre-
quency and one of them also in seizure intensity.
The dog who died had a definitive post-mortem diag-
nosis of GME (Fig. 1).
CSF and MRI
All dogs underwent control CSF (3 months after treat-
ment) and control MRI (6 months after treatment).
Table 1 Dog population, initial neurologic signs, and clinical diagnosis work-up
Case Breed Sex Age (years) Neurologic signs MRI CSF
1 Labrador
retriever
M 4 Acute onset of tremors, severe
ataxia, cervical pain
Single brainstem lesion, hyperintense in T2
and FLAIR, variable contrast enhancement
Mononuclear
pleocytosis
2 Chihuahua M 4 Acute onset of depression,
compulsive walking, cervical pain
Normal Mononuclear
pleocytosis
3 Half-breed M 3 Acute onset of general tremors,
tetraparesis, cervical pain
Diffuse spinal cord lesion at C3-C4, hyperintense
in T2 and FLAIR, severe contrast enhancement
Mononuclear
pleocytosis
4 Golden
retriever
F 2 Acute onset of compulsive walking,
cervical pain, depression, tetraparesis
Normal Mononuclear
pleocytosis
5 Cocker
Spaniel
F 3.5 Peracute onset of circling, ataxia,
vision deficit, cervical pain
Multifocal lesions in both white and gray matter,
hyperintense in T2 and FLAIR, no contrast
enhancement
Mononuclear
pleocytosis
6 Poodle F 1 Acute onset of severe circling, head
tilt, seizures
Multifocal cerebrum and brainstem lesions,
hyperintense in T2 and FLAIR, no contrast
enhancement
Mixed pleocytosis
(lymphocytic/
mononuclear)
7 Yorkshire
terrier
M 1.5 Acute onset of alternate mental
status agitation-stupor, seizures
Diffused hyperintensity in T2 an FLAIR in all left
brain hemisphere, variable contrast enhancement
Mononuclear
pleocytosis
8 Boxer F 2 Peracute onset of severe cervical
pain and weakness, tremors, partial
seizures
Multifocal lesions hyperintense in T2 and FLAIR,
variable contrast enhancement
Mixed pleocytosis
(mainly mononuclear)
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At the time of presentation, CSF showed mixed pleo-
cytosis with >50 % mononuclear (monocytes/lympho-
cytes) cells, some neutrophils, and increased protein
concentration (>30 mg/dl) (Fig. 2). Within the selected
group of dogs, six patients showed multiple, single, or
diffuse intra-axial hyperintense lesions on T2W and
FLAIR images, variable T1W contrast enhancement,
gray and white matter lesions, and variable mass effect,
while two dogs had a negative MRI with positive CSF.
Three months after treatment, one dog still presented a
mononuclear pleocytosis (>8 cells/μl, represented by
monocytes and lymphocytes) but had normal CSF
6 months after treatment (Table 2). Six months after
treatment, five dogs had normal MRI; in two dogs, the
lesions initially detected appeared better, and in one,
MRI lesions were unchanged (Figs. 3 and 4). Two of
these dogs underwent MRI 12 and 24 months after
treatment and, at that time, were negative to the lesions
initially detected. All dogs remained free of any therapy
through the follow-up period, except for the two dogs
under anti-epileptic drug, and one dog that had repeated
MSC treatment after 1 year due to reappearance of mild
ataxia. Seven dogs of the group are alive at present time
(Table 2).
Histopathology
Post-mortem histological examination revealed lesions
limited to the CNS, characterized by dense aggregates of
inflammatory cells arranged in perivascular cuffs. Le-
sions mainly involved the white matter of the telenceph-
alon, caudal brain stem, cerebellum, and cervical spinal
cord. Involvement of meninges related to lesions of
white matter directly underlying was also observed. The
inflammatory cell aggregates were composed principally
of macrophages admixed with lymphocytes and plasma
cells. Frequently, a focal eccentric accumulation of mac-
rophages within the perivascular cuffs was evident
(Fig. 1). In the most severely affected areas, the adjacent
nervous tissue was edematous and a diffuse dissemin-
ation of mononuclear cells was observed. No bacteria,
protozoa, or fungi were detected by the histochemical
stainings. The morphological pattern of the inflammatory
lesions was consistent with a disseminated form of canine
granulomatous meningoencephalomyelitis (GME).
Discussion
The field of immune modulation is expanding rapidly in
the last few years in both human and veterinary medi-
cines. Many autoimmune diseases of the nervous system
in human medicine have been identified in veterinary
medicine. A classic example of autoantibody-mediated
disease is myasthenia gravis; in this disease, autoanti-
bodies have been shown to target the muscle acetylcho-
line receptor. Another example is the Guillain-Barré
Fig. 1 Histopathologic examination evidenced an angiocentric
inflammatory lesion in the cerebral white matter composed of
macrophages and mixed with lymphocytes and plasma cells
(hematoxylin and eosin, ×400)
Fig. 2 Cytological preparation of the cerebrospinal fluid of cases 2
(a) and 4 (b). a, b mononuclear pleocytosis. The cellular population
was mainly represented by monocytes, macrophages, and lymphocytes.
A small number of non degenerated neutrophils were also present
(May-Grunwald Giemsa stain, ×100)
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syndrome (GBS), where strong evidence supports an im-
portant role for antibodies to gangliosides [38]. Analog
diseases exist in veterinary medicine. In human medi-
cine, it is now well-established that a substantial propor-
tion of these diseases are associated with autoantibodies
directed against the extracellular domains of cell-surface
proteins which are critical in the regulation of neuronal
excitability. There are conclusive clinical and scientific
data to support the pathogenicity of the antibodies in-
cluding the correlation between antibody levels and se-
verity of clinical features in an individual and the
development of similar diseases in experimental animals
after antibody transfer [39]. Furthermore, serum levels
of some antibodies are usually higher than CSF levels.
Probably, the disease begins in the periphery and not
in the brain; however, upon relating to total IgG
Table 2 Initial treatment, BMMSC treatment, and follow-up
Case Initial treatment MSCS treatment (IT/IA/IV) 3 months (CSF) 6 months (MRI/CSF) 12 months (MRI/CSF) 24 months (MRI/CSF)
1 Prednisone IT+IA Negative MRI negative
2 Prednisone IT+IA Positive MRI negativeCSF
negative
3 PrednisoneCytarabine IT+IA Negative MRI betterCSF
negative
4 Prednisone IT+IV after 1 year also IT
+IA
Negative MRI negative MRI negativeCSF
negative
MRI negativeCSF
negative
5 PrednisoneCytarabine IT+IV Negative MRI better MRI unchangedCSF
negative
MRI unchangedCSF
negative
6 Prednisone, PB, levetiracetam IT+IV Negative MRI unchanged
7 Prednisone, PB IT+IV Negative MRI negative
8 Prednisone, PB, levetiracetam,
cytarabine
IT+IV Negative MRI negative
Fig. 3 Dorsal and transversal MRI images of brainstem MOU lesion before and 6 months after treatment. The first MRI exam (A1 and A2) showed
a single intra-axial hyperintense lesion (arrow) on the right side of brain stem, not too well-delineated, visible in T2-weighted sequences (A1) and
FLAIR sequences (A2). There was no evidence of the lesion in the control MRI exam (B1 and B2) performed 6 months later
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concentrations, this ratio is reversed showing “intra-
thecal synthesis” [40–42].
In human medicine, improvements were greatest in
the patients with autoimmune encephalitis after early
administration of steroid therapies [39]. Neurologists are
now frequently recognizing this condition as an
immunotherapy-responsive encephalopathy.
In veterinary medicine, neuroinflammation has been
investigated in several spontaneous canine CNS diseases.
Although the precise mechanism in MUO remains un-
clear, some findings suggest similarity to the mecha-
nisms described in human autoimmune encephalitis
[43–47]. While in human medicine, various mouse ex-
perimental autoimmune encephalitis were treated by cell
therapy [48], to the best of our knowledge, MSCs were
never used in similar pathologies in dogs. In the light of
these facts, and since the spontaneous dog’s model has
been accepted for the research on some human neuro-
muscular diseases, it is interesting to analyze the safety
and efficacy of MSCs treatment in the dog’s spontaneous
MUOs. This may open new therapeutic possibilities in
dogs that do not respond to standard therapy or those in
which standard therapy is impossible for different rea-
sons. Furthermore, if proved safe and efficient, this treat-
ment may contribute to create protocols for human
treatment of similar diseases.
In our study, the use of standardized laboratory proce-
dures and protocols permitted to produce, for each dog,
the adequate therapeutic BMMSC dose allowing us to
guarantee a comparable result. Furthermore, shortening
culture time to 12–14 days was of special benefit to the
dogs that presented the more severe clinical signs. Obtain-
ing major cell quantity permitted cryoconservation of
unused cells for an eventual future treatment. Alongside
the benefit to the patient, we noted that this possibility
helped the owners of the dogs to decide for BMMSC
treatment rather than euthanasia.
In our group of dogs, we could not find any short- or
long-term major adverse effect to the BMMSC therapy.
In the short term, the only dog, in which a transitory
hyperthermia was registered 24 h after treatment, had
no other clinical signs. Such a reaction, if indeed related
to the treatment, may be considered as a minor adverse
reaction. In the longest term, two dogs who underwent
MRI 12 and 24 months after BMMSCs treatment were
both free of any pathology visible by this method.
The use of autologous BMMSCs from the bone mar-
row in dogs with MUO was feasible. Intrathecal injec-
tion is a routine procedure that can be done by any
neurologist, while intra-arterial injection should be con-
sidered as a minor surgical procedure, since exposure of
the carotid artery is necessary; therefore, the participa-
tion of a surgeon is needed.
Early clinical improvement has been reported by
owners and referring veterinarians. Both reported im-
provement in the dog’s general conditions. In particular,
paraspinal hyperesthesia of the cervical region, which
was a major feature in all dogs, disappeared. This has
been confirmed in the first neurologic control 30 days
after treatment, together with improvement of the initial
behavior changes, depression, proprioception and pos-
tural reactions, ataxia, head tilt, and circling. Interest-
ingly, in seven dogs in which tramadol was used due to
paraspinal cervical pain during the waiting period for
treatment, owners reported only mild effects of this
therapy compared to BMMSCs’ effect. This result is in
Fig. 4 Sagittal T2 (FSE T2, TR 4710 TE 120; 3-mm slice thickness) through the cervical spine. a Before and b 40 days after initiation of therapy. a
shows increased intramedullary signal from mid of C2 until mid of C6 (arrowheads). The changes are consistent with inflammatory edema. b The
visible extent of the inflammation is significantly decreased—changes reach now from mid of C3 to the end of C4 (arrowheads)
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line with previous reports of amelioration of neuroin-
flammation and associated behavior in animal models of
neuropathic pain after a single intra-brain or IV injec-
tion of BMMSCs [35, 36].
Although theoretically, IV injection may be sufficient
and equally effective because BMMSCs exert peripheral
immunomodulation effects, we believe that IT- and IA-
injected BMMSCs, besides their local anti-inflammatory
and immunomodulation effects, may circulate with the
arterial blood flow and CSF having better possibility to
reach the affected areas in the CNS, inducing a superior
neurotrophic and neuroprotective effects.
Analyzing IT+IV compared to IT+IA administration
shows that they achieved similar response but in differ-
ent times. The group of dogs treated by IT+IA adminis-
tration showed a shorter time of reaction to therapy
compared to the group treated by IT+IV administration.
Even though IT+IA group was up to 8 days faster in im-
proving the clinical status, within 2 weeks, no difference
was registered in the clinical course of both groups. The
only dog treated twice also showed a more rapid re-
sponse to the IT+IA administration compared to the IT
+IV injections. This may be explained by the faster dis-
tribution of BMMSCs via the carotid artery.
Another interesting aspect is that recently, in human
medicine, it has become clear that a number of patients
with encephalitis associated with some antibodies com-
plexes have a specific seizure semiology. These patients
showed an excellent response to corticosteroids, often
administered after multiple anti-epileptic agents were in-
effective [49]. This response was paralleled by a decrease
in the antibody complex levels. The concept is particu-
larly well-demonstrated in patients with frequent sei-
zures whose seizure frequency is often dramatically
reduced with corticosteroids [49–51]. Three of the eight
dogs affected by MUO had seizures; in one case, they
were acceptably controlled with PB, with frequency of
once every 2 months. Nevertheless, other two dogs that
were treated with a combination of PB and levatiracetam
were unstable; one had three to four seizures a month
and the other one to two seizures a month.
Six months after they initiated the BMMSCs therapy,
both dogs had an average of one to two seizures every
45 days, and one presented a lower seizure intensity,
which contributed to the quality of life of both dogs and
owners. It may be possible that in these cases, seizures
were, at least partially, dependent on autoimmune
mechanisms.
Finally, as far as the long-term survival, it is worth-
while underline that all but one dog are alive at the
present time; they were treated from 1 to 4 years ago,
with overall median survival of 705 days. All the patients
conduct normal life; their veterinarians report normal
clinical status, except for the anticonvulsant therapy in
two cases, and the owners reported to be satisfied with
their initial decision to try the therapy. Literature and
various authors report an overall median survival, for
dogs treated with corticosteroids and second-line im-
munosuppressive protocol, of 240 to 590 days, while
dogs treated with corticosteroids alone or with lomus-
tine survive from 28 to 357 days.
Moreover, dogs often respond initially to corticoste-
roids, but relapses are common; sustaining remission
thus may require long-term high-dose corticosteroids or
administration of alternative immunosuppressive agents
whereby the undesirable side effects.
Conclusions
The use of autologous MSCs from the bone marrow in
dogs with MUO was feasible for both IT and IA injec-
tions, even though the second should be considered as a
minor surgical procedure. The dogs presented early im-
provement in their general and neurological conditions,
with particular effect on cervical pain. The group of dogs
treated by IT+IA administration showed a shorter time
of reaction to therapy compared to the group treated by
IT+IV administration. Six months after they initiated the
BMSCs therapy, both dogs under anti-epileptic therapy
has reduced the frequency and one of them also the in-
tensity, of seizures. The results of this study suggest that
BMMSC treatment in dogs affected by MUO is safe and
feasible. Furthermore, the treatment proved to be effect-
ive in reducing cervical pain and neurologic deficits,
probably due to anti-inflammatory and immunomodula-
tion effects. A much larger group of dogs is needed to
confirm these results as well as CNS histology in order
to better understand the underlying mechanisms.
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